Genflow Biosciences PLC Announces Director Dealings
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), Europe's only listed longevity company, has announced significant director dealings. The company's CEO, Dr. Eric Leire, has made a substantial insider purchase of 2,100,000 ordinary shares at 1.15 pence per share on the open market on March 27, 2025. The transaction was executed in London and disclosed in accordance with UK Market Abuse Regulation requirements.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), l'unica azienda europea quotata nel settore della longevità, ha annunciato significativi scambi di azioni da parte dei dirigenti. L'amministratore delegato dell'azienda, il Dr. Eric Leire, ha effettuato un notevole acquisto di 2.100.000 azioni ordinarie a 1,15 pence per azione sul mercato aperto il 27 marzo 2025. La transazione è stata eseguita a Londra ed è stata divulgata in conformità ai requisiti del Regolamento britannico sulle abusi di mercato.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), la única empresa de longevidad cotizada en Europa, ha anunciado importantes transacciones de directores. El CEO de la empresa, el Dr. Eric Leire, ha realizado una compra significativa de 2,100,000 acciones ordinarias a 1.15 peniques por acción en el mercado abierto el 27 de marzo de 2025. La transacción se llevó a cabo en Londres y se divulgó de acuerdo con los requisitos del Reglamento de Abuso del Mercado del Reino Unido.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), 유럽 유일의 상장된 장수 기업이 중대한 이사 거래를 발표했습니다. 회사의 CEO인 에릭 레이르 박사는 2025년 3월 27일에 2,100,000주 보통주를 주당 1.15펜스에 공개 시장에서 대규모로 매입했습니다. 이 거래는 런던에서 실행되었으며, 영국 시장 남용 규정 요구 사항에 따라 공개되었습니다.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), la seule entreprise cotée en Europe spécialisée dans la longévité, a annoncé d'importantes transactions de directeurs. Le PDG de l'entreprise, Dr. Eric Leire, a réalisé un achat important de 2 100 000 actions ordinaires à 1,15 penny par action sur le marché ouvert le 27 mars 2025. La transaction a été exécutée à Londres et divulguée conformément aux exigences de la réglementation britannique sur les abus de marché.
Genflow Biosciences (LSE:GENF)(OTCQB:GENFF), das einzige börsennotierte Unternehmen für Langlebigkeit in Europa, hat bedeutende Transaktionen von Direktoren bekannt gegeben. Der CEO des Unternehmens, Dr. Eric Leire, hat am 27. März 2025 einen erheblichen Insider-Kauf von 2.100.000 Stammaktien zu 1,15 Pence pro Aktie auf dem offenen Markt getätigt. Die Transaktion wurde in London durchgeführt und gemäß den Anforderungen der britischen Marktmissbrauchsverordnung offengelegt.
- CEO demonstrates confidence in company through significant personal investment of 2,100,000 shares
- None.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
LONDON, UNITED KINGDOM / ACCESS Newswire / March 28, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") the only longevity company listed in Europe, is pleased to announce that it has been notified that Dr. Eric Leire, CEO of the Company, has today purchased 2,100,000 ordinary shares in the Company at a price of 1.15 pence each on the open market.
Details of the transaction are set out below:
Name | Dr. Eric Leire |
|---|---|
Position | Chief Executive Officer |
Date of Purchase | 27 March 2025 |
Number of Ordinary Shares Purchased | 2,100,000 |
Price per Ordinary Share | 1.15p |
Total Consideration | £24,150 |
Nature of Transaction | Market purchase |
Total Shareholding Following the Transaction | 126,514,999 |
Interest in Ordinary Shares (percentage) |
NOTIFICATION AND PUBLIC DISCLOSURE OF A TRANSACTION BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
The following disclosure is made in accordance with the requirements of the UK Market Abuse Regulation and provides details in relation to the purchase of Ordinary Shares by a Director:
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||
a) | Name | Eric Leire | ||||||
2. | Reason for the Notification | |||||||
a) | Position/status | PDMR | ||||||
b) | Initial notification / Amendment | Initial notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
a) | Name | Genflow Biosciences Plc | ||||||
b) | LEI | 213800HVOFXRXVEGDN62 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
a) | Description of the Financial instrument, type of instrument | Ordinary Shares of £0.0003 | ||||||
| Identification Code | GB00BP2C3V08 | ||||||
b) | Nature of the transaction | Issue of ordinary shares | ||||||
c) | Price(s) and volume(s) |
| ||||||
d) | Aggregated information: Aggregated volume · Price | 2,100,000 Ordinary Shares 1.15 pence per Ordinary Share | ||||||
e) | Dates of the transactions | 27 March 2025 | ||||||
f) | Place of the transactions | London | ||||||
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
|
Corporate Brokers |
|
Capital Plus Partners Ltd | |
Jon Critchley, +44 0203 821 6168 |
|
|
|
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Expected to begin in 2025, Genflow's clinical trial aims to explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and Twitter/X.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
How many shares did Genflow Biosciences (GENFF) CEO purchase in March 2025?
What was the price per share for the GENFF CEO's recent stock purchase?
When did the Genflow Biosciences (GENFF) insider transaction take place?
What is significant about Genflow Biosciences (GENFF) in the European market?
